In February 2023, researchers at Karolinska Institutet published a study demonstrating the effectiveness of CAR T-cell therapy in mice with ovarian cancer. This immunotherapy involves programming the immune system’s T cells to target tumor cells.
The study found that mice treated with these engineered T cells experienced significant tumor reduction and extended survival, with some even achieving complete remission. The researchers are optimistic that this approach could lead to clinical trials for women with ovarian cancer.
AI in Ovarian Cancer Diagnosis
In January 2025, an international study led by Karolinska Institutet revealed that AI-based models can outperform human experts in identifying ovarian cancer from ultrasound images. Trained on over 17,000 images, the AI achieved an accuracy rate of 86.3%, surpassing both expert and non-expert examiners. This suggests that AI could become a valuable tool in diagnosing ovarian cancer, especially in settings with a shortage of ultrasound specialists.
Ongoing Research and Clinical Trials
Karolinska Institutet continues to engage in various research initiatives aimed at improving ovarian cancer outcomes. The Gynecologic Cancer research group, led by Henrik Falconer, focuses on clinical trials, cancer epidemiology, and translational research in gynecological malignancies. Their work includes the RACC trial, which explores the oncologic safety of robotic surgery for cervical cancer, and the IPLA-OVCA trial, investigating surgical interventions in ovarian cancer treatment.
Through these multifaceted research efforts, Karolinska Institutet aims to enhance the diagnosis, treatment, and overall prognosis of ovarian cancer, offering hope to patients worldwide.
(Photo source: CTTO)
